Similar articles

• Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma.

  Baltimore D, Witte ON, Yang L, Economou J, Ribas A. Baltimore D, et al. Pigment Cell Melanoma Res. 2010 Apr;23(2):288-9. doi: 10.1111/j.1755-148X.2010.00666.x. Epub 2010 Jan 7. Pigment Cell Melanoma Res. 2010. PMID: 20067554 No abstract available.
• Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.

  Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Roszkowski JJ, et al. Cancer Res. 2005 Feb 15;65(4):1570-6. doi: 10.1158/0008-5472.CAN-04-2076. Cancer Res. 2005. PMID: 15735047
• Cancer. Cancer immunotherapy is more than a numbers game.

  Offringa R. Offringa R. Science. 2006 Oct 6;314(5796):68-9. doi: 10.1126/science.1133893. Science. 2006. PMID: 17023641 No abstract available.
• Is adoptive T-cell therapy for solid tumors coming of age?

  Pedrazzoli P, Comoli P, Montagna D, Demirer T, Bregni M; EBMT STWP. Pedrazzoli P, et al. Bone Marrow Transplant. 2012 Aug;47(8):1013-9. doi: 10.1038/bmt.2011.155. Epub 2011 Aug 1. Bone Marrow Transplant. 2012. PMID: 21804611 Review.
• Generation of tumor-specific T-cell therapies.

  Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H. Morris E, et al. Blood Rev. 2006 Mar;20(2):61-9. doi: 10.1016/j.blre.2005.05.001. Epub 2005 Jun 22. Blood Rev. 2006. PMID: 15978709 Review.